BLBD three-lens brief
Evidence-based stock research on BLBD. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Negative free cash flow last quarterly (-$10.41M).
- 50-day MA below 200-day MA (death-cross regime); price below both.
- P/E of 6.8 — trading at a value multiple.
- Analyst mean target $90.14 — 57% above current (7 analysts).
- Negative free cash flow last quarterly (-$10.41M).
- Earnings scheduled 2026-11-23.
BLBD closed at $57.56 (+0.38%) as of 2026-11-12. Market cap: $1.96B. P/E (trailing) 6.8. Price is below the 50-day MA and below the 200-day MA. Positives: p/E of 6.8 — trading at a value multiple.; analyst mean target $90.14 — 57% above current (7 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; negative free cash flow last quarterly (-$10.41M).. Last quarter: Revenue $517.16M, net income $185.25M, free cash flow -$10.41M. Watching for: 2026-11-23 earnings release (11 days out).
Why three lenses on BLBD, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BLBD across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BLBD" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BLBD brief"></iframe>